People who reach the age of 110 and beyond may owe part of their extraordinary longevity to an immune system that keeps adapting to new threats rather than simply wearing out. A study of blood samples from some of the oldest people alive has found that these supercentenarians carry unusually large numbers of a rare immune cell capable of killing abnormal cells. The cells not only become more common with age but expand into large families of nearly identical copies, a sign that the immune system is still actively responding to challenges in extreme old age.
The rare cells at the center of the study
The immune cells in question are called CD4 cytotoxic T lymphocytes, or CD4 CTLs, a hybrid type of T cell that remains scarce for most of a person’s life. These cells have previously been shown to kill tumor cells in certain cancers, and during illness they can reproduce rapidly to help the body fight infection. New research published in the Cell Press journal Cell Reports suggests that this same kind of immune activity may be associated with healthy aging in people who live past 110.
A steady rise across the decades
The team examined blood from 28 adults sorted into three age groups: 70 to 99, 100 to 109, and 110 and older. The median proportion of CD4 CTLs climbed steadily across those groups, from about 4 percent of T cells in the youngest cohort to 9.6 percent among people aged 100 to 109 and 17.6 percent among those 110 and older. In other words, in the oldest group these normally rare cells made up nearly one in five of all T cells measured.
The pattern suggests the expansion tends to begin around age 100, though it was not strictly tied to age. One participant younger than 100 actually had the highest proportion of CD4 CTLs seen anywhere in the study, a reminder that individual immune profiles vary widely.
The result runs counter to a long-standing assumption about aging, which holds that the immune system steadily deteriorates over the decades in a process sometimes called immunosenescence. If the immune systems of the oldest people were simply exhausted, these specialized killer cells would be expected to fade rather than multiply. Instead the data show them growing more prominent at precisely the ages when the body is thought to be most vulnerable, hinting that whatever allows a person to reach 110 may involve an immune system that stays engaged rather than one that quietly winds down.
Large clones point to a persistent fight
To understand why the cells grow so abundant, the researchers analyzed the participants’ T cell receptors, the molecular tags that identify what each cell recognizes. The analysis indicated that clonal expansion, in which a single cell copies itself many times over, plays a central role. Among the participants, the largest individual clone accounted for an average of 33.3 percent of all CD4 CTLs, and in one centenarian a single clone made up 53.8 percent of them.
That concentration suggests some of the oldest adults are mounting sustained responses to ongoing threats. When the team compared the receptor sequences of each person’s dominant clone against a public database, nearly three dozen matches came from people who had been diagnosed with lung, breast or liver cancers. None of the supercentenarians in the study had those cancers, leading the researchers to propose that the cells may reflect early responses to abnormal or potentially cancer-related targets.
What the research does and does not show
First author Kosuke Hashimoto, an associate professor at the University of Osaka in Japan, framed the results as evidence that immune aging is not simply a process of decline. The study, published August 19 and also indexed with a permanent identifier through the journal’s DOI record, argues that the selective expansion of certain T cells suggests the immune system may keep adapting to age-related challenges even at the extreme end of the human lifespan.
The findings come with firm limits. The work was cross-sectional, meaning it captured a single snapshot rather than tracking people over time, so it cannot show that the cells caused anyone to live longer. The number of participants was small, an unavoidable constraint given how few people ever reach 110, and a handful of blood samples cannot establish whether abundant CD4 CTLs are a cause of longevity, a consequence of it, or simply a marker of some other underlying trait. The researchers measured T cells circulating in the blood and do not yet know what the cells are doing in tissues elsewhere in the body, where their targets remain unidentified.
Hashimoto said the next step is to investigate how CD4 CTLs behave inside human tissues, work that could reveal whether the cells are actively clearing damaged or precancerous cells or merely accumulating without effect. Understanding that behavior could eventually inform efforts to bolster immune function in older adults more broadly, although any such application is speculative and far off. For now, the study adds a detailed piece to the puzzle of exceptional longevity, suggesting that the immune systems of the very oldest people may be defined less by exhaustion than by continued adaptation to the threats that accumulate with age.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- More than 60,000 people flee the Spokane area as complex fires overrun 600 structures
- 11 engines built to run well past 200,000 miles
- Card skimmers hidden on gas pumps and ATMs are draining accounts, and here’s the tell
- The FBI says hackers are hijacking outdated home routers, and it named the models to check
